Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description

(2016) Francesca Meacci et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

(2016) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

(2016) Jürgen Braun et al.   BIOLOGICALS

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases

(2016) Stefano Gentileschi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

(2015) Elena Nikiphorou et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

(2015) J. Sieczkowska et al.   Journal of Crohns & Colitis

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

(2015) Yoon Suk Jung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The challenge of indication extrapolation for infliximab biosimilars

(2014) Brian G. Feagan et al.   BIOLOGICALS

Physicochemical characterization of Remsima®

(2014) Soon Kwan Jung et al.   mAbs

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Interchangeability, immunogenicity and biosimilars

(2012) Hans C Ebbers et al.   NATURE BIOTECHNOLOGY